Skip to main content

Table 1 Demographic and clinical characteristics of study participants: results are expressed as percentages for categorical variables and mean ± standard deviation for continuous data

From: The relative importance of frailty, physical and cardiovascular function as exercise-modifiable predictors of falls in haemodialysis patients: a prospective cohort study

Variables

All patients

(69)

Fallers

(26)

Non-fallers

(43)

P-value

Sociodemographic characteristics

 Sex (% M)

55.1

42.3

62.8

0.097

 Age (years)

61.7 ± 13.3

58.3 ± 14.1

63.8 ± 12.6

0.151

 Weight (kg)

80.3 ± 18.7

75.7 ± 18.6

83.1 ± 18.5

0.114

 Height (cm)

166.2 ± 9

166 ± 9

166.3 ± 9

0.892

 BMI (kg * m−2)

29.1 ± 6.4

27.6 ± 7

30 ± 5.9

0.144

Clinical history

 Dialysis vintage (days)

713 ± 714

732 ± 636

701 ± 765

0.465

 CCI (score)

5.3 ± 2.2

5.1 ± 2.1

5.4 ± 2.3

0.639

Primary renal disease (%)

Diabetic nephropathy

25

26.9

23.8

0.773

Glomerulonephritis

19.1

19.2

19

1.000

Polycystic kidney

8.8

0

14.3

0.075

Renovascular or hypertensive

8.8

0

14.3

0.075

Other

20.6

23.1

19

0.690

Uncertain aetiology

17.6

30.8

9.5

0.046

Type of vascular access (%)

Arteriovenous fistula

64.7

61.5

66.7

0.667

Central-venous

35.3

38.5

33.3

0.667

Inter-dialytic weight gain (kg)

1.6 ± 1.2

1.6 ± 1

1.6 ± 1.4

0.923

Ultrafiltration rate (mL/kg/h)

6.5 ± 2.4

7.1 ± 2.5

6.1 ± 2.3

0.095

HD treatment time (h)

4.1 ± 0.5

4.1 ± 0.4

4.2 ± 0.5

0.395

Prescribed medications

 Medications (n°)

11.8 ± 3.4

12.4 ± 3.3

11.5 ± 3.5

0.262

 Beta blockers use (%)

50

42.3

54.8

0.318

 ACE-inhibitors use (%)

7.4

7.7

7.1

1.000

 Ca-channel blockers use (%)

57.4

50

61.9

0.335

 AngII-receptor antagonists use (%)

16.2

11.5

19

0.512

 Alpha blockers use (%)

32.4

38.5

28.6

0.397

 Antihypertensive use (%)

83.8

80.8

85.7

0.737

  > 1 antihypertensive use (%)

51.5

42.3

57.1

0.234

 Opiates use (%)

19.1

11.5

23.8

0.342

 Antidepressants use (%)

33.8

50

23.8

0.027

 Diuretics use (%)

33.8

23.1

40.5

0.141

Laboratory values

 Hb (g/dL)

11.2 ± 1.2

11 ± 1

11.2 ± 1.2

0.317

 CRP (mg/L)

25.8 ± 45.4

37.6 ± 59.2

18.3 ± 32.7

0.027

 Bicarbonate (mmol/L)

21.2 ± 3.2

21.5 ± 3.1

21.1 ± 3.4

0.546

 Na (mmol/L)

139 ± 2.8

138.4 ± 3.3

139.4 ± 2.4

0.388

 K (mmol/L)

4.6 ± 0.7

4.6 ± 0.7

4.6 ± 0.6

0.992

 Urea (mg/dL)

16.4 ± 5.1

15.7 ± 6.1

16.7 ± 4.5

0.276

 Phosphate (mmol/L)

1.5 ± 0.6

1.5 ± 0.6

1.5 ± 0.5

0.978

 PTH (ρmol/L)

27.2 ± 32.1

28.9 ± 43.4

26.2 ± 23.1

0.586

 Albumin (g/L)

37.1 ± 4.3

36.1 ± 5.2

37.7 ± 3.7

0.146

 Adjusted calcium (mmol/L)

2.4 ± 0.1

2.3 ± 0.1

2.4 ± 0.1

0.511

 URR (%)

71.1 ± 6.2

71.1 ± 7.7

71 ± 5.1

0.994

 Creatinine (μmol/L)

638.1 ± 161.3

592 ± 175.7

666 ± 147.1

0.064

  1. Abbreviations: BMI body mass index, CCI Charlson comorbidity index, HD haemodialysis, ACE angiotensin-converting enzyme, Ca calcium, AngII angiotensin II, Hb hemoglobin, CRP C-reactive protein, Na sodium, K potassium, PTH parathyroid hormone, URR urea reduction ratio